Physician profile
Mark Horowitz
NPI 1669413878
$1,277.65
in general payments reported to CMS, 2019-2025
19 companies · $13.12 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $361 · 2021: $105 · 2022: $25.70 · 2023: $52.29 · 2024: $71.06 · 2025: $13.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $271.39 | 2019-2024 | |
| Galderma Laboratories, L.P. | $206.54 | 2019-2024 | |
| Allergan, INC. | $170.40 | 2019-2020 | |
| Janssen Biotech, INC. | $130.44 | 2019-2024 | Tremfya |
| Medimetriks Pharmaceuticals, INC. | $96.89 | 2020-2021 | |
| Abbvie INC. | $76.11 | 2020-2023 | |
| Leo Pharma INC. | $55.47 | 2019-2020 | |
| Lilly USA, LLC | $39.41 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $38.69 | 2019 | |
| Amgen INC. | $34.66 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.86 | 2019 | |
| Genzyme Corporation | $23.60 | 2019 | |
| Strata Skin Sciences, INC. | $19.38 | 2020 | |
| Aclaris Therapeutics, INC. | $19.26 | 2019 | |
| Genentech USA, INC. | $17.59 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.95 | 2021 | |
| Organon LLC | $13.12 | 2025 | Vtama |
| Mission Pharmacal Company | $12.35 | 2019 | |
| Mayne Pharma Commercial LLC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.